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One thousand one hundred and twenty-eight candi-
dates for liver transplantation were stratified into five 
urgency-of-need categories by the United Network for 
Organ Sharing (UNOS) criteria. Most patients of 
low-risk UNOS 1 status remained alive after 1 yr 
without transplantation; the mortality while waiting 
was 3% after a median of 229_5 days. In contrast, only 
3% of those entered at the highest risk UNOS 5 category 
survived without transplantation; 28% died while 
waiting, the deaths occurring at a median of 5.5 days. 
The UN08 categories in between showed the expected 
gradations, in which at each higher level fewer pa-
tients remained as candidates throughout the l-yr du-
ration of study while progressively more died at earlier 
and earlier times while waiting for an organ. In a 
separate study of posttransplantation survival during 
the same time period, the best postoperative results 
were in the lowest-risk UN08 1 and 2 patients (88% 
combined), and the worst results were those in UNOS 5 
(71%). However, a relative risk cross-analysis showed 
that a negative benefit of transplantation may have 
been the result in terms of l-yr survival for the low-risk 
elective patients, but that a gain in life extension was 
achieved in the potentially lethal UNOS categories 3, 4 
and 5 (greatest for UN08 3). These findings and conclu-
sions are discussed in terms of total care of patients 
with liver disease, and in the context of organ allo-
cation policies of the United States and Europe. (HEPA-
TOLOGY 1994;20:56S-628.) 
Many of the earlier presentations at this Consensus 
Development Conference have focused on specific dis-
eases and the wisdom of performing liver replacement 
for disorders that are apt to recur (such as cancer, 
hepatitis and alcoholic cirrhosis). Others have discussed 
limiting the operation to prime-of-life candidates, with 
exclusion of the very young or aged. Expansion of the 
donor pool has been proposed in the "splitting" oflivers 
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that are shared between two candidates or in the use of 
liver fragments from living donors. These subjects have 
been judiciously addressed in the context of organ 
shortage and allocation, leaving the all-important ques-
tions of patient disease severity and complexity almost 
untouched. To focus on this problem, Bronsther et al. (1) 
have analyzed elsewhere and we present here in more 
detail the dynamics in a collection of more than a 
thousand adult patients who were given candidacy in 
our program. The results may be useful in policy 
determination about organ allocation and in definition 
of the role of liver transplantation in the total arma-
mentarium available to treat hepatic diseases. 
MATERIALS AND METHODS 
ea.e Material. The records were reviewed of 1,208 con-
secutive adult patients who became transplant candidates at 
the University of Pittsburgh Medical Center between January 
1,1989, and December 31, 1990. The patients were stratified 
at the time of candidacy activation into one of the five United 
Network of Organ Sharing (UNOS) categories, defined as 
follows: (1) working; (2) home (many still working) but 
requiring close medical supervision, sporadic hospital care or 
both; (3) hospital-bound continuously or most of the time; (4) 
intensive care unit-bound; and (5) UNOSta.t, meaning a life 
expectancy of only a few days without transplantation. In 80 
cases, chart data were insufficient for accurate classification. 
The remaining, 1,128 patients constituted the study popu-
lation. Of these, 129 (11.4%) were activated to candidacy at 
lowest risk category 1, 160 (14.2%) were category 5 and the 
remainder fell in between (Table 1). Hepatic diagnoses were 
parenchymal diseases with cirrhosis (62%), cholestatic dis-
orders (18%), malignancy without or usually with cirrhosis 
(10%), inborn metabolic errors (3%) and miscellaneous condi-
tions including fulminant liver failure (7%). 
Evaluation of Candidate Stability. All 1,128 patients were 
followed on the waiting list for 1 yr unless their observation 
was terminated during this time for reasons of death or 
transplantation. The date of entry on the waiting list was 
designated T 1 for everyone. The date of exit was called T 2 in the 
event of transplantation. The exit of nontransplant patients 
was designated T 3' a value that was 365 days for those who 
survived without transplantation for the entire year and less 
than this for those who died while waiting for a graft. The 
interrelationship of these three time points is summarized in 
Figure 1. For those who came to transplantation during the 
year, the waiting time (W) was calculated with the formula 
W = T 2 - T l' Survival while waiting for those without trans-
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TABLE 1. UNOS status at entry to waiting list 
UNOS status Frequency ('I'D) 
1 
2 
3 
4 
5 
TOTAL 
129 (11.4) 
203 (18.0) 
408 (36.2) 
228 (20.2) 
160 (14.2) 
1,128 (100.0) 
TABLE 2. Demographic information on 691 consecutive 
primary adult liver transplants, 7/1/89-12/31/90 
Median follow-up 
Range 
Primary immunosuppression 
Cyclosporinea 
FK506 
M/F ratio 
Age (yd 
UNOS classification at time of transplant 
1,2 
3 
4 
5 
aFK 506 was available if necessary. 
bData expressed as mean ± S.D. 
22.4 mo 
1.0-39.1 mo 
314 (45.4%) 
377 (54.6%) 
405:286 
47.7 ± 12.3 
85 (12.4%) 
260 (37.6%) 
174 (25.2%) 
172 (24.9%) 
plantation (Z) was calculated as Z = T 3 - T l' From these 
data, the median times were determined for exit, transplan-
tation or death while waiting with each UNOS entry category. 
To capture disease progression while waiting, we recorded each 
patient's UNOS status when they exited the waiting list (at 
time point T 2 or T 3)' 
POIIttra7l8piantation Survival. In addition, postoperative 
survival was determined for 691 consecutive patients who had 
primary liver transplantation from July 1,1989, to December 
31, 1990, the last 18 mo of the candidacy study. These 
recipients were not all derivative from the candidates under 
study because about 10% of them were already on the waiting 
list before January 1, 1989. The profiles of the transplant 
recipients, including their final UNOS scores are summarized 
in Table 2. 
This separate study was undertaken so that we might have 
a better assessment of survival expectation at the various risk 
levels than was available, even in the current literature. Just 
before this series began, there had been two significant 
improvements with a potential impact on high-risk (as well 
as all other) patients: University of Wisconsin solution in 
1988 (2, 3), and, perhaps more important, FK 506, which 
after July 1989 could be used for primary immunosup-
pression or for the rescue of patients whose initial baseline 
drug was cyclosporine (4, 5). 
By cross analysis of those results and those from the 
candidacy study, it was possible to compare the risk of 
mortality after liver transplantation (treatment group) with 
the risk of mortality on the waiting list (no treatment group). 
This was expressed as the relative risk (RR) score. 
Statiatical Analysis. The Kruskal-Wallis test, a nonpara-
metric test equivalent to one-way ANOV A, was used to 
compare the median times to exit, transplantation or death 
while waiting with each UNOS entry category. The x2 test of 
Waiting lime to transplantation 
W = T,- T. (W s 365 days) 
Dale of ActivaUon (TI, 
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Dace of exil with Transplantation (T2) 
Survival on the waiting list 
Z = T, . T. (Z s 365 days) 
Date of exil without Transptantatlon (i3) 
• palienl death while wailing 
• alive at 365 days 
• inactivaledlk>ss at follow-up 
FIG. 1. Schematic representation of events occurring within 365 
days of activation on the liver transplant waiting list. 
association was used to compare percent mortality across the 
different UNOS risk categories. 
Patient survival after transplantation during the study 
period was calculated from the date of liver transplantation 
until patient death. Survival curves were generated with the 
Kaplan-Meier (product-limit) method and were compared by 
means of the generalized Wilcoxon (Breslow) test. A p value 
less than 0.05 on comparison of UNOS categories was 
considered statistically significant. 
The methods of Crowley and Hu (6) and Kalbfleisch and 
Prentice (7) were adapted to investigate whether liver trans-
plantation is life extending at different levels of pretransplant 
risk. A proportional-hazards model was used to assess the 
effect of liver transplantation, allowing us to use the partial-
likelihood approach of Cox (8) and to avoid specification of a 
model for the underlying baseline hazard function (or force of 
mortality) assumed conventionally to be common to all 
individuals. Because the candidacy list was a mixed population 
consisting of patients with high forces of mortality (UNOStat) 
and patients with low forces of mortality (UNOS 1), the 
assumption of a common hazard was invalid, necessitating 
stratification into the entry subgroups defined according to 
UNOS criteria. In the Cox proportional hazards model, liver 
transplantation was incorporated as a time-varying covariate. 
Patients who were alive at 1 yr, lost to follow-up, given 
transplants elsewhere or inactivated (these were considered 
lost to follow-up) were right censored (Le., exact survival time 
for each patient is unknown but failure or death is assumed to 
occur sometime in the future). 
Relative risk (RR) was computed by means of Cox regression 
analysis as a measure of the associated risk of mortality due to 
liver transplantation. The analysis excluded patients whose 
medical urgency status changed as a result of disease pro-
gression on the waiting list. Therefore estimates of RR were 
based on a homogeneous subgroup of patients whose pretrans-
plant risk was similar to their risk at activation. This was done 
so that we might avoid any bias in the RR attributable to 
disease progression. 
An RR greater than 1.0 during the year's observation 
indicated an increased risk of mortality after transplantation 
relative to that in the steadily declining population of candi-
dates who did not have this intervention. An RR less than 1.0 
indicated a reduction in mortality attributable to transplan-
tation. Approximate 95% confidence intervals were generated 
according to Woolfs method (9). Statistical analyses were 
performed with statistical software package EGRET (10). 
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TABLE 3. Median time to exit from the waiting list stratified by UNOS score at enrollment 
UNOS StatWi at Time of Activation 
Features 1 (n = 129) 2 (n = 203) 3 (n = 408) 4 (n = 228) 5 (n = 160) P Value" 
Median time to exit (days) 365 80 34 16 5 <0.00001 
Range (days) 2-365 1-365 0-365 0-365 0-365 
Patients given transplants (%) 36 72 80 73 67 <0.00001 
Median time to transplant (days) 97 58 30 14 5 <0.00001 
Range (days) 2-360 1-332 0-322 0-123 0-73 
Died while waiting (%) 3 4 10 18 28 <0.00001 
Median time to death (days) 229.5 30 33.5 13 5.5 <0.00001 
Range (days) 114-345 4-325 4-325 2-30 0-64 
Alive without transplant (%) 56 15 6 4 3 <0.00001 
Lost to follow-up (%) 5 9 4 6 2 0.0242 
"Based on comparisons across all UNOS status at activation. 
TABLE 4. UNOS score at time of candidacy activation vs. time of transplantation 
UNOS score at trllDBplantation 
UNOS score at enrollment 1 2 
1 28.3% 15.2% 
2 0% 38.4% 
3 0.3% 2.7% 
4 0% 3.6% 
5 0% 0% 
RESULTS 
Dynamics on. the Waiting List. Waiting-list dynamics 
are summarized for all risk categories in Table 3. Most 
patients (56%) entered as UNOS 1 passed through the 
year without transplantation, excluding 5% who were 
lost to follow-up. Most of the 5% had improved under 
medical management or had been treated with conser-
vative surgical procedures (most commonly, distal 
splenorenal shunt) with discharge from the candidacy 
clinic to distant referring physicians. The median 
waiting time for UNOS 1 patients was 365 days (range, 
2 to 365 days). Four patients (3%) exited by dying after 
a wait of 114 to 345 days (median, 229.5 days). Of the 36 
who exited by transplantation, almost three fourths had 
graduated to a higher risk category (discussed in the 
next section), including three recipients with calamitous 
complications tha.t vaulted them to UNOStat. 
The median time of waiting before exit decreased with 
each successive increase in entry risk category: from 365 
days in UNOS 1 to 80 days in UNOS 2 and only 5 days 
in UNOS 5. Exit by death while waiting occurred with 
the same kind of sliding scale, at a median time of 229.5 
days in UNOS 1, 1 rno in UNOS 2, 13 days in UNOS 4 
and 5 days in UNOS 5 (Table 3). The frequency of this 
distressing outcome rose from 3% to 28% from UNOS 1 
to UNOS 5; this was reflected in the decline of exit by 
transplantation. Most of the small number of patients in 
UNOS classes 3 to 5 who were alive at the year's end 
without transplantation had entered with the diagnosis 
of fulminant or subfulminant liver failure. 
Survival Studies. The variable stability of con-
secutive patients coming to transplantation over an 
3 4 5 TOTAL 
34.8% 15.2% 6.5% 100% 
34.2% 17.1% 10.3% 100% 
56% 26% 15% 100% 
26.2% 47% 23.2% 100% 
9.3% 18.5% 72.2% 100% 
1S-mo period can be seen in Table 4, which relates the 
entry UNOS score to the score on the day of transplan-
tation. Of those entered as UNOS 1, only 28.3% were 
still in this category at the time of liver replacement. The 
other 71.7% had UNOS grade slippage to a higher risk 
category, including UNOS 4 and 5. 
The same trend was seen in all risk categories. Of 
interest, however, was the fact that classification to a 
lower risk status was not uncommon during waiting in 
the dangerous UNOS 4 and 5 classes. This reflected 
benefit of supportive care allowing the patients to be 
removed from the intensive care unit or occasionally 
even discharged home under close surveillance. 
Six-month and 1-yr survival rates were equivalent in 
patients whose UNOS status was class 1 to class 3 at the 
time of transplantation. It was slightly but not signifi-
cantly less in the UNOS 4 group and significantly 
decreased in UNOS 5 (p = 0.002). Between 1 and 2 yr, 
the percentage of patient losses was least (3.5%) in the 
originally highest risk UNOS 5 group (Table 5). 
Graft survival curves were similar to those of patient 
survival but about 10% lower at 6, 12 and 24 rno (Table 
6). The difference in patient (Table 5) and graft survival 
rates (Table 6) reflected the benefit of repeat transplan-
tation. 
The overall rate of repeat transplantation at any time 
during the study was 17.1% (Table 7). The rate of 
repeat transplantation was incongruously highest in 
the UNOS 1 and 2 categories and lowest in the UNOS 
4 group (NS). 
RR Score. Although the failing and unstable patients 
were systematically pruned from the candidacy list by 
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TABLE 5. Actuarial percent patient survival 
Time Overall 
6 rna 84.9 :!: 1.4" 
1yr 82.0 :!: 1.5 
2yr 76.B :!: 1.6 
p = 0.0017, UNOS 5 vs. combined UNOS 1-4. 
"Data expressed as survival :!: S.E. 
1,2 
88.2:!: 3.5 
88.2:!: 3.5 
80.7:!: 4.3 
UNOS classification 
3 4 5 
89.2 :!: 1.9 85.6:!: 2.7 76.0 :!: 3.3 
87.3 :!: 2.1 B1.6:!: 2.9 71.4 :!: 3.5 
B2.1 :!: 2.4 76.4 :!: 3.3 67.9 :!: 3.6 
TABLE 6. Actuarial percent graft survival 
Time Overall 
6 mo 75.B :!: 1.6" 
1yr 72.2 :!:: 1.7 
2yr 68.3 :!:: 1.B 
p = 0.0175, UNOS 5 vs. combined UNOS 1-4. 
"Data expressed as survival :!: S.E. 
1,2 
78.B :!: 4.4 
76.9:!: 2.6 
72.7 :!:: 4.9 
transplantation, creating a dwindling pool of "no-
treatment" survivors, the highly elective UNOS 1 
group was particularly interesting because about 54% 
went through the l-yr period of observation in the 
same risk category without transplantation. In this 
subgroup and in the smaller, similar one of UNOS 2, 
those who remained had a higher l-yr cumulative 
survival than did patients who underwent transplan-
tation at their original UNOS entry level. This was in 
contrast to the lethal outcome of those who did not 
have transplantation after entry with UNOS classifi-
cations of 3, 4 and 5. 
Statistically expressed (Table 8), the RR score from 
transplantation in the UNOS 1 and 2 cohorts exceeded 
1.0, connoting a potential negative benefit of trans plan-
tation in spite of the high rate (88%) of 1-yr posttrans-
plant survival. In contrast, patients entered and kept at 
UNOS classifications of 3, 4 and 5 had RR scores ofless 
than 1.0, showing treatment value. The most favorable 
RR outcome was found in UNOS 3 patients. 
DISCUSSION 
Although transplantation has become a dominant 
factor in hepatology, the role of this procedure and the 
appropriate time for its application have yet to be fully 
defined (11-15). We have presented a one-dimensional 
examination in which extension of life was the focus, 
excluding the improved quality of life that must be a 
pervasive consideration. This monolithic approach is 
dismissive of quality-of-life considerations and ignores 
extremely frail candidates with severe disease or other 
factors not reflected in the UNOS score. These latter 
patients are in a narrow window of opportunity that is 
closed with any significant pretransplant complication. 
Their identification (epitomized by the older patient 
with PBC) requires sophisticated clinical judgment at a 
hands-on level. 
UNOS classification 
3 4 5 
BO.B :!: 2.4 75.9 :!: 3.2 66.7:!: 3.6 
71.B :t 3.4 68.7:t 3.5 63.2:!: 3.7 
68.7 :t 3.5 68.7 :t 3.5 60.7:!:: 3.B 
However, a surprising number of elective UNOS 1 and 
2 patients are physically functional but disabled in part 
because they perceive their disease as inexorable. For 
such transplant candidates, of whom some have ad-
equate or restorable liver function, there may be other, 
and often safer, treatments. This is exemplified medi-
cally by autoimmune hepatitis, the progression of which 
can be delayed with the same drugs used to prevent 
rejection, putting off the need for transplantation for 
years, or perhaps permanently in some cases (16). 
Surgeons also can often offer treatment short of 
transplantation to patients who are still in good con-
dition. Henderson et al. (17) emphasized the neglected 
role of distal splenorenal shunt for good-risk patients 
whose principal complication was variceal hemorrhage, 
pointing out that the 3- and 5-yr survival rates after this 
procedure were superior to those of the admittedly 
sicker transplant recipients at the same institution 
(Emory University). In their study, the quality-of-life 
score was essentially the same in both groups 1 yr after 
either kind of operation, but the cost was less than a 
quarter that for those treated with Warren shunts. 
To have access to these and other therapeutic alter-
natives, the patient with liver disease must be treated 
at a hepatology center where all of the medical tools 
and surgical procedures that have been acquired over 
the years are available. Otherwise, the introduction 
of liver transplantation, detached from its historical 
roots in hepatology and general surgery, will degrade 
instead of advance the care of the patient with liver 
disease. 
Our investigation provided an assessment of the risk 
of attempts at conservative care by quantitating the rate 
of slippage of patients from one UNOS risk category to 
another while waiting for transplantation, as well as the 
mortality during this period in candidates who were 
prospectively determined to be at low, medium or high 
I 
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TABLE 7. UNOS classification and need for repeat transplantation 
UNOS classification at time of initial trausplant 
No. of grafts 
One 
Multiple 
1,2 (n = 85) 
67 (78.8%) 
18 (21.2%) 
3 (n = 260) 
217 (83.5%) 
43 (16.5%) 
4 (n = 174) 
149 (85.6%) 
25 (14.4%) 
5 (n = 172) 
140 (81.4%) 
32 (18.6%) 
TOTAL (n = 691) 
573 (82.9%) 
118 (17.1%) 
TABLE 8. RR of mortality with liver transplantation stratified by UNOS classification at time of enrollment using Cox's 
proportional-hazards model 
UNOS score at 
enrollment and exit RR 
1 (n = 78) 3.375 
2 (n = 71) 2.098 
3 (n = 162) 0.273 
4 (n = 77) 0.352 
5 Cn = 81) 0.528 
risk. The results were remarkably similar to those of a 
similar study by Gordon et al. (15) of the candidate 
population of the mid-1980s, a time when far fewer liver 
centers offered transplant services. Although few in this 
analysis, those in our analysis who underwent trans-
plantation after entry with good UNOS risk factors had 
a very high survival rate at 1 yr (88%). Yet their survival 
was not as high as actually realized by the nontransplant 
good-risk residual patients who did not undergo this 
procedure. Only when the urgency status reached 
UNOS 3 was there an obvious gain in survival. 
This was not surprising in view of the results in 
historical series of patients who came to transplantation 
with generally more advanced disease than the cross-
section of potential recipients who are admitted to 
candidacy today. One such study was of patients with 
PBC treated by transplantation from March 1980 
through June 1987 at the universities of Colorado and 
Pittsburgh (18). The cases were studied retrospectively 
by physicians at the Mayo Clinic who independently 
stratified the patients into three categories -low, 
midrange and high. The sickest patients had the worst 
results after transplantation. Only 58% of those at 
highest preoperative risk survived for 1 yr, compared 
with 74% with an intermediate degree of illness and 83% 
for those with the most favorable preoperative scores. 
Using the Mayo prognostic model for PBC (19) which 
combined five factors at the time of transplantation (age, 
serum bilirubin, serum albumin, prothrombin time and 
edema index), we compared with the posttransplant 
results those predicted by this model without transplant 
intervention. This analysis showed a 58% gain in 
survival at 1 yr in the highest-risk patients (average 
preoperative bilirubin, 28 mg/dl) , 55% in the interme-
diate group (bilirubin, 24 mg/dl) but only 14% in the 
best-risk cohort (bilirubin, 12 mg/dl) , whose predicted 
l-yr survival without transplantation had been 69%. 
The degree of rehabilitation of the survivors and the 
death rate after 1 yr were the same no matter how sick 
the patients were at surgery (18). 
95% Confidence limits 
Lower Upper pVaIue 
0.342 33.33 0.298 
0.608 7.243 0.241 
0.126 0.594 0.001 
0.141 0.881 0.026 
0.206 1.355 0.184 
Similar trends were reported in good-, intermediate-
and high-risk patients with the diagnosis of sclerosing 
cholangitis (20) whose actual posttransplant outcomes 
were compared with those predicted with a second Mayo 
prediction model (21) derived from age, bilirubin, 
splenomegaly and histopathological stage. The percent 
gain in survival of best-risk patients in the first year 
compared with that in their surrogate controls was a 
modest 7%; even after 7 yr, the percentage difference 
was still only 7% (60% vs. 53%). In contrast, the 
highest-risk recipients achieved a 40% gain in survival 
by 12 mo, an improvement that had grown to nearly 80% 
after 4 yr, when all were predicted to be dead by the 
Mayo model. By 7 yr, the best absolute results (80%) 
were from the patients who had been the most ill at the 
outset because there had been no deaths after 18 mo in 
this cohort. 
With the five-tier UNOS score, a study of adults and 
children with heterogeneous diagnoses at the New 
England Medical Center (1984-1992) showed the same 
effect of disease severity on survival and correlated in 
addition the preoperative status with costs, including 
those incurred before transplantation (13), which in our 
own experience may exceed those after transplantation. 
Each higher level of risk added to the expenditures in 
this study. The elective UNOS 1 and 2 recipients lived 
35% more frequently than did those in the UNOStat 
stage 5 (88% vs. 53%), with UNOS 3 and 4 recipients in 
between. Yet, in those who survived to undergo quality-
of-life (Karnofsky) testing 1 yr later (the majority in 
every subgroup), the scores were the same no matter 
what the preoperative risk score. 
In all such analyses, the significant salvage of doomed 
UNOS 4 and 5 recipients with catastrophic disease has 
been at least as noteworthy as the fact that the survival 
curve was degraded by their admission into candidacy 
and that their care was costly. Such complete and 
repeated reversal of fortune of patients with liver disease 
was without precedent before the availability of trans-
plantation. The results in our survival study were 
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congruent with the earlier ones, but the gap between 
urgency classes had narrowed to the point of nonsignifi-
cance except for the UNOS 5 (UNO Stat) group which 
trailed the other four groups by 10% at 6,12 and 24 mo. 
Still, even in this highest-risk cohort, 71% and 68% of 
the patients were alive at 1 and 2 yr. Mter this time, 
further decay in survival had no relation to preexisting 
illness. 
Although there was a high proportion of profoundly ill 
patients on the candidacy list during the study period, 
care was provided with reasonable efficiency because of 
the two key features of the organ allocation system then 
operational: emphasis on urgency of patient need and an 
interlocking national donor reservoir designed to meet 
this need as mandated by the Gore-Waxman-Kennedy 
law (1985). The national character of the system was 
changed on January 1, 1991, by a directive from UNOS 
that created a confederacy of regions from which the free 
national movement of organs was discouraged in favor of 
elective regional use. 
The directive secondarily removed urgency of need 
from the American organ allocation framework as its 
most pervasive national objective because it permitted or 
even encouraged the elective use of organs in some parts 
of the country while candidates languished elsewhere in 
the progressively more lethal UNOS stages 3, 4 and 5. 
This has been justified increasingly by the argument 
that high-risk recipients survive less frequently after 
transplantation than those with lesser need. Our study 
has verified this conclusion, but our RR analysis has 
added the disturbing possibility that the elective use of 
livers for low-risk recipients could result in their net loss 
of life in at least a l-yr framework while retarding the 
use of these organs for patients who otherwise have little 
hope of survival. Similar observations and questions 
have been raised by critical appraisals of heart trans-
plantation (22). 
The selective exclusion of seriously ill patients from 
candidacy is an administrative syndrome of subtle triage 
that has been encouraged with the establishment of 
minimum life survival standards by government 
agencies or insurance carriers as a measure of transplant 
team competence, without stratification of disease se-
verity (23). The incentive that this will create to divert 
transplant services from those who could benefit most 
has been noted by Kilpe, Krakauer and Wren (24) of the 
United States Bureau of Policy Development, Office of 
Coverage and Eligibility Policy, Health Care Financing 
Administration. An even more powerful disincentive to 
treat ill patients could be the growing tendency of in-
surance carriers to pay a fixed fee to hospitals per liver 
transplant case. The predictably higher cost of providing 
life-saving vs. elective liver transplantation has been dis-
cussed. 
These may be uniquely our problems in the United 
States, but this seems doubtful. The best-known Eu-
ropean system of allocation is probably more patient-
driven than the current American one, but only indi-
rectly. It regulates organ distribution on the basis of case 
production by a given team during a preceding 6-mo 
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interval. A stipulated level of life survival is required, but 
without a means of case stratification. This would seem 
to present a temptation to anyone lacking a strong 
character to churn out easy cases with an eye to the 
organ supply 6 mo down the line, skipping over those 
whose less certain salvation is more apt to cause 
monumental headaches in the operating room and 
afterward. 
Rather than having center-driven organ allocation, 
autoregulation of the supply-and-demand balance would 
be accomplished with less micromanagement by having 
organ distribution reflect patient need. This could 
actually ameliorate the organ shortage by encouraging 
the use of alternative therapies for patients with 
minimal risk factors, particularly if the possibility 
identified in our RR analysis is confirmed that there is a 
potential negative survival effect from premature trans-
plantation. At the other extreme, the wastage of organs 
by teams with the compulsion to treat inappropriate 
. diseases or hopelessly ill patients could be an unde-
sirable consequence of a system driven by urgency. 
However, monitoring to curb such practices would be 
easy because this kind of activity is so readily detected. 
Equally detectable is the "cheating" by misclassification 
of which each center is inclined to accuse all others. 
Although this may occur in isolated cases, the analyses 
herein presented showed that the stability (or insta-
bility) while waiting and death rate as well as time to 
death during this interval were in strict conformity to 
what was expected from the UNOS entry score. 
Finally, it is important to consider the ripple effect of 
allocation policy on organ supply. If lifesaving need does 
not translate into the kind of prompt response that 
requires a large donor pool, a sobering effect will be 
shrinkage of the organ availability by more than the loss 
of public confidence. Livers with minor functional or 
anatomic imperfections, or from older donors, will be 
systematically discarded in regions with a superfluity of 
organs. Even if they were procured, such donor organs 
would not be accepted elsewhere if the perception or the 
reality exist that prompt rescue will be unavailable or 
difficult in the event that such a "marginal" organ fails. 
It would seem that an organ pool for the united countries 
of Europe would be just as important as for the United 
States of America. 
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